CBio Ltd.
www.cbio.com.au
Latest From CBio Ltd.
BioNotebook: Targacept gone in reverse merger with Catalyst, plus five other deals
After a string of failures, Winston-Salem, North Carolina-based Targacept and its neuronal nicotinic receptor (NNR) therapeutics will be replaced by engineered human proteases for hemophilia and complement-mediated disorders in a reverse merger with privately-held Catalyst Biosciences in South San Francisco.
New treatments for rheumatoid arthritis target underlying pathology
What do the French impressionist painter Pierre-Auguste Renoir and South African heart surgeon Christiaan Barnard have in common? They both depended on extreme manual dexterity in their chosen careers. How remarkable, then, that they both suffered from the debilitation condition, rheumatoid arthritis.
Ex-EMA head Thomas Lönngren must wait two years before joining pharma firms
Thomas Lönngren, the former head of the European Medicines Agency (EMA), will probably have to relinquish all or some of the commercial appointments that he has taken up since his departure from the agency. EMA said on 21 March that Mr Lönngren must wait two years before he takes up a position with the private sector pharmaceutical industry. The announcement follows controversy over a potential conflict of interest after Mr Lönngren joined private sector companies shortly after leaving the EMA.
Start-Up Quarterly Statistics, Q3 2010
Company Information
- Industry
-
Biotechnology
- Large Molecule
- Pharmaceuticals
- Therapeutic Areas
- Immune Disorders
- Inflammation
- Musculoskeletal & Connective Tissue Disorders
- Alias(es)
- Ownership
- Public
- Headquarters
-
Worldwide
-
Australia
-
Australia
- Parent & Subsidiaries
- CBio Ltd.
- Senior Management
-
Jason Yeates, CEO & Managing Dir.
Dennis Feeney, MD, Executive Dir. & Pres., Global Dev. & Licensing - Contact Info
-
CBio Ltd.
Phone: (61) 7 3841 4844
Brisbane Technology Park
85 Brandl St.
Eight Mile Plains, 4113
Australia
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice